- Applying the OMOP Common Data Model to Facilitate Benefit-Risk Assessments of Medicinal Products Using Real-World Data from Singapore and South Korea
-
Tan HX, Teo DCH, Lee D, Kim C, Neo JW, Sung C, Chahed H, Ang PS, Tan DSY, Park RW, Dorajoo SR
- KMID: 2529793
- Healthc Inform Res.
- 2022 Apr;28(2):112-122.
- doi: 10.4258/hir.2022.28.2.112
Objectives: The aim of this study was to characterize the benefits of converting Electronic Medical Records (EMRs) to a common data model (CDM) and to assess the potential of CDM-converted... -
- CITED
-
- Close
- SHARE
-
- Close
